Audited Financial Result for the Financial Year 31st March, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts more than Nifty Microcap 250 and 0.9 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Amkay Products Ltd reported audited FY25 results with revenue from operations rising to ₹3,839.01 lakhs from ₹3,106.91 lakhs in FY24, a growth of about 23.6%. Total revenue (including other income) grew to ₹3,970.84 lakhs from ₹3,231.83 lakhs. Profit before tax stood at ₹429.77 lakhs versus ₹350.10 lakhs in the prior year, while profit after tax for FY25 was ₹263.00 lakhs. Basic EPS declined slightly to ₹3.96 from ₹4.13 in FY24. The statutory auditor (M/s R K Jagetiya & Co.) issued an unmodified opinion, and the board also appointed M/s Pimple & Associates as Secretarial Auditor and M/s Soni Punit & Associates as Internal Auditor for FY26.
Strong top-line growth of over 20% is a positive signal, but EPS dipped marginally year-over-year, suggesting margin pressure. Shareholders should view this as healthy revenue expansion with slightly weaker per-share profitability.